Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic Squamous Non-Small Cell Lung Cancer”

263 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 263 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07442565
What this trial is testing

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 506
Large-scale testing (Phase 3)UnknownNCT01656551
What this trial is testing

MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIIB
National Cancer Institute, Naples 232
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Looking for participantsNCT06953089
What this trial is testing

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumors
DualityBio Inc. 492
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Large-scale testing (Phase 3)Looking for participantsNCT07291037
What this trial is testing

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca 400
Large-scale testing (Phase 3)Study completedNCT02264990
What this trial is testing

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
AbbVie 595
Testing effectiveness (Phase 2)Ended earlyNCT05469178
What this trial is testing

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Who this might be right for
Carcinoma, Non-Small-Cell Lung
BerGenBio ASA 26
Testing effectiveness (Phase 2)Study completedNCT03548467
What this trial is testing

Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Locally Advanced or Metastatic Solid Tumours
Nykode Therapeutics ASA 41
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Large-scale testing (Phase 3)Looking for participantsNCT04181060
What this trial is testing

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Ended earlyNCT05070247
What this trial is testing

TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Pancreatic CancerHepatocellular CancerMesothelioma+7 more
Takeda 61
Early research (Phase 1)Study completedNCT00397384
What this trial is testing

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Who this might be right for
Adenocarcinoma of the ColonAdenocarcinoma of the RectumAdvanced Adult Primary Liver Cancer+64 more
National Cancer Institute (NCI) 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT05017025
What this trial is testing

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more
M.D. Anderson Cancer Center 32
Testing effectiveness (Phase 2)Study completedNCT01561456
What this trial is testing

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Who this might be right for
Non-small-cell Lung CancerSquamous Cell CarcinomaAdenocarcinoma of the Lung
Axelar AB 100
Large-scale testing (Phase 3)Looking for participantsNCT06670196
What this trial is testing

SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 420
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Load More Results